Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Abstract

Objective: To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents.

Methods: Patients (N=505) were randomised (1:1:1) to placebo, apremilast 20 mg twice daily, or apremilast 30 mg twice daily. Rescue therapy with apremilast was designated at week 16 for placebo patients not achieving 20% improvement in swollen and tender joint counts. At week 24, the remaining placebo patients were then randomised to apremilast 20 mg twice daily or 30 mg twice daily. The efficacy and safety of apremilast were assessed over 52 weeks.

Results: At week 16, significantly more patients receiving apremilast 20 mg twice daily (28%) and 30 mg twice daily (41%) achieved 20% improvement in American College of Rheumatology response criteria versus placebo (18%; p=0.0295 and p<0.0001, respectively), and mean decrease in the Health Assessment Questionnaire-Disability Index score was significantly greater with apremilast 30 mg twice daily (-0.20) versus placebo (-0.07; p=0.0073). In patients with baseline psoriasis body surface area involvement ≥3%, significantly more apremilast 30 mg twice daily patients achieved 50% reduction from baseline Psoriasis Area and Severity Index score (41%) versus placebo (24%; p=0.0098) at week 16. At week 52, observed improvements in these measures demonstrated sustained response with continued apremilast treatment. Most adverse events were mild to moderate in severity; the most common were diarrhoea, nausea, headache and upper respiratory tract infection.

Conclusions: Apremilast demonstrated clinically meaningful improvements in psoriatic arthritis and psoriasis at week 16; sustained improvements were seen with continued treatment through 52 weeks. Apremilast was generally well tolerated and demonstrated an acceptable safety profile.

Trial registration number: NCT01212770.

Keywords: Ankylosing Spondylitis; Psoriatic Arthritis; Treatment.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1

Patient disposition through week 52. *Includes withdrawal by patient, lost to follow-up, protocol violation, non-compliance, other. †Includes patients initially randomised to placebo, who met early escape criteria and were then randomised to apremilast at week 16. ‡Includes patients initially randomised to placebo who were then randomised to apremilast at week 24 for the active treatment phase (week 24–52). AE, adverse event.

Figure 2

ACR20 (A), HAQ-DI (B), SJC and TJC (C) and PASI-50 (D) at week 16. *p†p≤0.0001 versus placebo, based on analysis of covariance model for HAQ-DI, SJC and TJC, and Cochran-Mantel-Haenszel test for ACR20 and PASI-50 for the intent-to-treat population; patients who discontinued or did not have sufficient data were counted as non-responders (ACR20 and PASI-50) or had their last observation was carried forward (HAQ-DI, SJC and TJC). Error bars represent SE. ACR, American College of Rheumatology; BSA, body surface area; HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI-50, 50% reduction from baseline Psoriasis Area and Severity Index; SJC, swollen joint count; TJC, tender joint count.

Figure 3

Over 52 weeks, ACR20 (A), HAQ-DI (B), PASI-50 (C), SJC (D) and TJC (E) (data as observed). Error bars represent SE. ACR, American College of Rheumatology; BSA, body surface area; HAQ-DI, Health Assessment Questionnaire-Disability Index; n/m=number of responders/number of patients with sufficient data for evaluation; PASI-50, 50% reduction from baseline Psoriasis Area and Severity Index score; SJC, swollen joint count; TJC, tender joint count.